PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
70.89%
Net income growth above 1.5x CRWV's 7.67%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
17.98%
D&A growth well above CRWV's 26.15%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-104.31%
Both reduce yoy usage, with CRWV at -110.52%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-104.31%
Negative yoy usage while CRWV is 112.72%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
No Data
No Data available this quarter, please select a different quarter.
-0.95%
Both yoy CFO lines are negative, with CRWV at -510.76%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-29.06%
Both yoy lines negative, with CRWV at -74.30%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
-327.51%
Negative yoy purchasing while CRWV stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
No Data
No Data available this quarter, please select a different quarter.
-9.92%
We reduce yoy other investing while CRWV is 202.79%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-126.20%
Both yoy lines negative, with CRWV at -70.42%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
-41.55%
Negative yoy issuance while CRWV is 4.88%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
25.19%
Buyback growth of 25.19% while CRWV is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.